LYRA insider filings
Lyra Therapeutics, Inc. — 46 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-05-15. Screen LYRA transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for LYRA between 2026-07-10 and 2026-10-08. The table below lists the most recent filings on record.
Recent insider filings — Lyra Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-15 | 4 | Smith W Bradford — Director | Disposition to issuer (D): 640 @ $0 | EDGAR |
| 2026-04-03 | 4 | Palasis Maria — Principal Executive Officer, Director | Disposition to issuer (D): 2,000 @ $0 | EDGAR |
| 2026-04-03 | 4 | Cavalier Jason — Principal Financial Officer | Disposition to issuer (D): 667 @ $0 | EDGAR |
| 2026-01-08 | 4 | Cavalier Jason — Chief Financial Officer | Sale (S): 769 @ $3.36 | EDGAR |
| 2026-01-08 | 4 | Palasis Maria — President & CEO, Director | Sale (S): 1,702 @ $3.36 | EDGAR |
| 2025-11-13 | 4 | PERCEPTIVE ADVISORS LLC — 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD — 10% owner Perceptive LS (A), LLC — 10% owner EDELMAN JOSEPH — 10% owner | Sale (S): 4,783 @ $4.31 · Sale (S): 537 @ $4.31 · Sale (S): 7,862 @ $4.06 · Sale (S): 883 @ $4.06 · Sale (S): 28,597 @ $3.90 · Sale (S): 3,213 @ $3.90 | EDGAR |
| 2025-11-10 | 4 | PERCEPTIVE ADVISORS LLC — 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD — 10% owner Perceptive LS (A), LLC — 10% owner EDELMAN JOSEPH — 10% owner | Sale (S): 28,902 @ $5.18 · Sale (S): 3,247 @ $5.18 · Sale (S): 17,746 @ $4.75 · Sale (S): 1,993 @ $4.75 · Sale (S): 16,633 @ $4.54 · Sale (S): 1,869 @ $4.54 | EDGAR |
| 2025-10-08 | 4/A | Palasis Maria — President & CEO, Director | Holdings only — no transactions reported | EDGAR |
| 2025-10-03 | 4 | Palasis Maria — President & CEO, Director | Grant/award (A): 3,667 (derivative) @ $0 | EDGAR |
| 2025-07-14 | 4 | Palasis Maria — President & CEO, Director | Sale (S): 1,565 @ $8.91 | EDGAR |
| 2025-07-14 | 4 | Cavalier Jason — Chief Financial Officer | Sale (S): 684 @ $8.91 | EDGAR |
| 2025-05-16 | 4 | snyderman nancy lynn MD — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Smith W Bradford — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | MERRIFIELD C ANN — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | TOBIN JAMES R — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2025-01-10 | 4 | Palasis Maria — President & CEO, Director | Grant/award (A): 800,000 @ $0 | EDGAR |
| 2025-01-10 | 4 | Cavalier Jason — Chief Financial Officer | Grant/award (A): 420,000 @ $0 | EDGAR |
| 2024-12-11 | 4 | Palasis Maria — President & CEO, Director | Grant/award (A): 183,333 (derivative) @ $0 | EDGAR |
| 2024-12-11 | 4 | Waksal Harlan — Executive Chair, Director | Grant/award (A): 128,333 (derivative) @ $0 | EDGAR |
| 2024-10-18 | 4 | Palasis Maria — President & CEO, Director | Grant/award (A): 300,000 @ $0 | EDGAR |
| 2024-10-18 | 4 | Cavalier Jason — Chief Financial Officer | Grant/award (A): 100,000 @ $0 | EDGAR |
| 2024-06-14 | 4 | ALTMAN MICHAEL SETH — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Poukalov Konstantin — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | snyderman nancy lynn MD — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Smith W Bradford — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | MERRIFIELD C ANN — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | TOBIN JAMES R — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-03-20 | 4 | Waksal Harlan — Executive Chair, Director | Grant/award (A): 275,000 @ $0 | EDGAR |
| 2024-03-20 | 4 | Palasis Maria — President & CEO, Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2024-02-01 | 4 | Nieman Richard — Chief Medical Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2024-02-01 | 4 | Cavalier Jason — Chief Financial Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2024-02-01 | 4 | Bishop John E — Chief Technology Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2023-11-13 | 4 | Waksal Harlan — Executive Chair, Director | Purchase (P): 25,000 @ $2.96 | EDGAR |
| 2023-07-12 | 4/A | Palasis Maria — President & CEO, Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2023-07-05 | 4 | Poukalov Konstantin — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-07-05 | 4 | ALTMAN MICHAEL SETH — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-07-05 | 4 | snyderman nancy lynn MD — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-07-05 | 4 | Smith W Bradford — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-07-05 | 4 | MERRIFIELD C ANN — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-07-05 | 4 | ANDERSON EDWARD T — Director, 10% owner | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-07-05 | 4 | TOBIN JAMES R — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-06-26 | 4 | Palasis Maria — President & CEO, Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2023-06-02 | 4 | ANDERSON EDWARD T — Director, 10% owner | Purchase (P): 403,858 @ $2.43 · Purchase (P): 197,946 @ $2.43 · Purchase (P): 1,203,612 @ $2.43 · Purchase (P): 201,929 (derivative) @ $0.12 · Purchase (P): 98,973 (derivative) @ $0.12 · Purchase (P): 601,806 (derivative) @ $0.12 | EDGAR |
| 2023-06-02 | 4 | PERCEPTIVE ADVISORS LLC — Director, 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD — 10% owner Perceptive LS (A), LLC — 10% owner EDELMAN JOSEPH — Director, 10% owner | Purchase (P): 3,610,832 @ $2.49 · Purchase (P): 1,805,416 (derivative) | EDGAR |
| 2023-06-02 | 4 | NBVM GP, LLC — 10% owner DAMORE RICHARD A — 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP — 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP — 10% owner North Bridge Venture Partners VI L P — 10% owner North Bridge Venture Management V, L.P. — 10% owner North Bridge Venture Management VI, L.P. — 10% owner | Purchase (P): 403,858 @ $2.43 · Purchase (P): 197,946 @ $2.43 · Purchase (P): 1,203,612 @ $2.43 · Purchase (P): 201,929 (derivative) @ $0.12 · Purchase (P): 98,973 (derivative) @ $0.12 · Purchase (P): 601,806 (derivative) @ $0.12 | EDGAR |
| 2023-02-28 | 4 | Bishop John E — Chief Technology Officer | Grant/award (A): 220,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Lyra Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-04-17 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2026-04-10 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2026-03-16 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-02-27 | 8-K | 2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement | EDGAR |
| 2026-02-06 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-01-12 | 8-K | ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events | EDGAR |
| 2025-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-04 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-22 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2025-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=LYRA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →